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The role of anti-tumor immune responses in oncolytic adenoviral therapy has not been well studied due to lack of efficacious tu-
mor model in immunocompetent mice. Here, we evaluated the contributions of immune components to the therapeutic effects of 
oncolytic adenoviruse in an immunocompetent murine tumor model permissive for infection and replication of adenovirus. We 
found that CD8+ T cells were critical mediator for antitumor efficacy by oncolytic adenovirus. Intratumoral viral therapy induced 
intensive infiltration of CD8+ T cells in tumor, increased tumor-specific IFN- (interferon-) production and CTL (cytotoxic T 
lymphocyte) activity of lymphocytes, and generated a long-term tumor-specific immune memory. Boosting CD8+ T cell responses 
by agonistic anti-4-1BB (cluster differentiation 137, CD137) antibody showed synergistic anticancer effects with oncolytic viro-
therapy. Our results provide insight into antitumor mechanisms of oncolytic adenovirus in addition to their direct oncolytic effect. 
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Cancer is a leading cause of death worldwide and there is a 
critical need for novel cancer therapies. Primary tumors are 
currently treated by a combination of therapies including 
surgery, local radiotherapy, chemotherapy and antibody 
targeted therapies, which have been traditionally known to 
directly destroy or eliminate tumor cells. However, various 
studies recently showed that the host anti-tumor immune 
responses also play a critical role in the therapeutic effects 
of these conventional antitumor regimens [1,2].  
Replication-selective oncolytic viruses are a rapidly ex-
panding therapeutic platform for cancer. Adenovirus (Ad) 
has been the most commonly described oncolytic virus in 
the recent decade due to their efficacy, safety and ease of 
manipulation [3]. Oncolytic Ad vectors infect and kill can-
cer cells as a result of the normal Ad life cycle by replicat-
ing in cells and releasing progeny viruses. These vectors 
rely on replication and spread through the tumor to achieve 
efficacy. However, the replication of oncolytic virus is quite 
immunogenic and the influence of immune responses on the 
oncolytic therapy is complex. Even though several studies 
showed that suppressing the immune system enhances the 
efficacy of oncolytic vectors, recent preclinical and clinical 
evidence suggests that antitumor efficacy is partially medi-
ated by the immune response [4–6].  
Adenoviral replication is generally species specific, and 
it was assumed by many that viral replication would not 
occur in mouse tumors [7]. Consequently, oncolytic adeno-
viral vectors are commonly evaluated in immunodeficient 
mouse-human tumor xenograft models. However, this mod-
el does not accurately reflect how oncolytic adenovirus 
might behave in human because these mice lack an intact 
immune system [6,8]. We previously screened a large panel 
of mouse carcinoma cell lines for their ability to support 
adenovirus uptake, earl gene expression, late gene expres-
sion, replication and cytopathic effects (CPE) and identified 
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four carcinoma lines with variable permissivity for adeno-
viral gene expression, cytopathic effects and/or replication. 
The antitumor efficacy of adenovirus serotype 5 (Ad5) was 
significantly higher in CMT-93 model than that in other 
three tumor models. Moreover, the efficacy of Ad5 against 
CMT-93 tumors was markedly less in athymic mice than in 
immunocompetent mice [9,10]. Here, we studied the roles 
of T cell responses in the tumor therapy of oncolytic adeno-
viruse by tansplanting murine rectal tumor CMT93 into 
immunocompetent C57B/6 mice as a tumor model. We 
found that antitumor efficacy of oncolytic adenovirus is 
dependent on CD8+ T cell response, which can be enhanced 
by anti-4-1BB Ab treatment, a potent promoter of anti-  
tumor CD8+ T cell responses. 
1  Materials and methods 
1.1  Animals  
Female C57BL/6 mice aged 6–8 weeks were purchased 
from Wei Tong Li Hua experimental animal center (Beijing, 
China). All studies involving animals were approved by the 
Institutional Laboratory Animal Care and Use Committee. 
1.2  Cell lines, adenoviruses and antibodies 
Murine rectal cell line (CMT93), murine non-small-cell 
lung cancer cell line (CMT64) were maintained in RPMI 
1640 (Hyclone, Laboratory Inc, Logan, UT, USA) supple-
mented with fetal bovine serum (10%, Hyclone), L-glutamine 
(2 mmol/L, Hyclone), penicillin (100 IU/mL), and strepto-
mycin (50 g/mL, Hyclone,). Adenovirus serotype 5 (Ad5) 
was grown on HEK-293 cells as previously described [11].  
Anti-mouse CD137 (cluster differentiation 137) agonist 
mAb (clone 2A, rat IgG2a) was described previously [12]. 
Rat anti-KLH mAb (rat IgG2a) or rat IgG (Sigma-Aldrich, St. 
Louis, MO, USA) was used as control. All mAbs, including 
anti-CD8 (TIB210, rat IgG2a), anti-NK1.1 (PK136, rat 
IgG2a), anti-CD4 (GK1.5, rat IgG2b), and Rat anti-KLH 
mAb (rat IgG2a), used as control Ig, were purified from asci-
tes of nude mice and treated with Triton-X 114 for LPS  
removal. 
1.3  In vivo antitumor efficacy by oncolytic adenovirus 
and lymphocyte depletion 
1×106 CMT93 tumor cells in 100 L PBS were injected 
subcutaneously into the right flank of mice. 1×109 plaque- 
forming units (pfu) virus were injected intratumorally on 
days 8, 11, and 14 after tumor establishment. The injections 
were introduced through a single central tumor puncture site 
and 3–4 needles tracts were made radially from the center 
while virus was injected as the needle was withdrawn. CD4, 
CD8 or NK (natural killer) cells were depleted by intraperi-
toneal injection of anti-CD4 (GK1.5), anti-CD8 (TIB210), 
or anti-NK1.1 (PK136) mAbs at 200 g respectively twice a 
week from the day before the viral therapy. For tumor re-
challenge experiments, tumor free mice from virotherpay 
were kept for three months and then rechallenged with 
2×106 CMT93 in the left flank (contrary side to the first 
inoculation). For combination therapy of Ad5 and an-
ti-4-1BB mAb, CMT93 tumor-bearing mice were intra-
tumorally injected with 1×109 pfu of Ad5 or PBS on days 
12, 15 and 18 after tumor inoculation, and intraperitoneally 
with anti-4-1BB mAb or control Ig on days 14, 19 and 24. 
Tumor dimensions were measured every 3 d using a digital 
caliper (111-103-20G, Guilin Guanglu Measuring Instru-
ment Co., Ltd., Guilin, China), and the volume of the tu-
mors was calculated using the formula: volume = 0.52 × 
length × width × width. 
1.4  CTL activity assays   
Splenocytes were isolated from the mice 7 d after the last 
Ad5 administration and co-cultured with mitomycin C 
(MMC, 100 μg/mL)-treated CMT93 cells for 4 d as CTL 
effector cells. CMT93 cells or CMT64 tumor cells were 
used as target cells. The CTL activity were determined by 
lactate dehydrogenase (LDH) release assay with CytoTox 
96® Non-Radioactive Cytotoxicity Assay kit (Promega, 
Madison, WI, USA) according to the manufacturer’s in-
structions. In brief, target cells were washed three times 
with RPMI 1640, and mixed with effector cells at effec-
tor-to-target (E/T) ratios of 6:1, 13:1, or 40:1 in a 96-well 
round-bottomed plate. The wells containing exclusively 
effector cells, target cells, or culture medium, respectively, 
were served as controls to estimate the LDH background. 
After 4 h incubation, 50 L supernatant from each well was 
transferred to the corresponding well of enzymatic assay 
plate. 50 L reconstituted substrate mix was added to each 
well. After 30 min incubation, the reactions were stopped 
by adding 50 L stop solution and measured with an ELISA 
reader (Plate CHAMELEON, Hidex, Finland) at 490 nm. 
The percentage of specific lysate was calculated as 100 × 
(experimental release−spontaneous release)/(target maxi-
mum release−target spontaneous release).  
1.5  Histopathology staining 
The harvested tumor tissues were fixed with 10% formalde-
hyde and embedded in paraffin. The cross section was depar-
affinized and stained with hematoxylin and eosin solution.  
Frozen tumor tissues were cut into 5-μm sections and 
placed on polylysine-coated slides. After blocking with 3% 
hydrogen peroxide (H2O2) in methanol and goat serum, the 
slides were stained with rat anti-mouse CD8 (Clone 53-6.7, 
R&D) mAb overnight at 4°C. The slides were incubated 
with goat anti-rat IgG conjugated with horseradish peroxi-
dase. 3-amino-9-ethy-carbazole solution was added as the 
substrate for peroxidase activity (Zhongshan Goldenbridge 
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Biotech, Beijing, China). For statistic analysis of CD8+ T 
cell number in tumor tissues stained with anti-CD8 Ab, five 
fields (200×) were randomly selected in each tumor section 
and photographed with a camera (DFC300 FX Digital Color 
Camera, Leica Microsystems AG, Schmidt Marketing & 
Trading Ltd., Guangzhou, China). The pictures were ana-
lyzed by Image J image processing soft (NIH, USA) for 
CD8+ T cell number in each sample. The results were ex-
pressed as the median of CD8+ cells per mm2, n=5. 
1.6  Detection of IFN- production by ELISA   
Splenocytes and tumor draining lymph node cells were 
stimulated with MMC-treated tumor cells in complete 
RPMI 1640 medium for 3 d. Supernatants were collected 
for the detection of IFN-γ (interferon-γ) by using IFN-γ 
ELISA kit (BD PharMingen, San Diego, CA, USA). 
1.7  Statistical analysis 
Statistical analysis was performed with GraphPad Prism 5 
software (GraphPad Software Inc., San Diego, CA, USA). 
Error bars represent standard error of the mean. Two-tailed 
unpaired Student’s t test was used. P value < 0.05 was con-
sidered to be significant. 
2  Results 
2.1  Therapeutic efficacy of intratumoral Ad5 treat-
ment is dependent on CD8+ T cell responses in immu-
nocompetent mice  
We previously found that adenovirus (Ad5) therapy could 
eliminate CMT-93 rectal tumors subcutaneously trans-
planted in immunocompetent syngeneic mice, but the effica-
cy of Ad5 against CMT-93 tumors was significantly less in 
athymic mice [9]. This result suggested that adaptive immun-
ity play an important role in oncolytic adenoviral therapy.  
To determine the components of adaptive immune re-
sponse which are involved in the antitumor effect elicited 
by Ad5 therapy, the mice bearing subcutaneous CMT93 
tumor were intratumorally injected with Ad5 at days 8, 11 
and 14 after tumor inoculation and intraperitoneally injected 
with anti-CD8, anti-CD4 or anti-NK1.1 deletion mAbs re-
spectively every 5 d from the day before the viral therapy. 
Adequate depletion of immune cells was evaluated by flow 
cytometry of peripheral blood from the mice (data not 
shown). As shown in Figure 1(a), intratumoral treatment of 
Ad5 resulted in the tumor regression in control antibody- 
treated mice, and depletion of NK or CD4+ T cells did not 
affect the anti-tumor effect of Ad5 therapy. However, de-
pletion of CD8+ T cell almost abrogated the antitumor ac-
tivity of Ad5 therapy. Histological examination of the 
treated tumor tissues also showed extensive leukocytic in-
filtration in Ad5-treated tumors compared with PBS-treated   
 
Figure 1  Intratumoral adenovirus therapy is mediated by CD8+ T cells in 
an immunocompetent mouse model. C57B/6 mice were inoculated subcu-
taneously with 1×106 CMT93 cells. The established tumors were injected 
directly with 1×109 plaque-forming units (pfu) of Ad5 or PBS (control) on 
days 8, 11, and 14. (a) The deletion antibodies of anti-CD4 (NK1.5), anti- 
CD8 (TIB210) and anti-NK1.1 (PK136) or control antibody (control Ig) 
were intraperitoneally administrated twice a week, starting on day 7. Tu-
mor sizes of individual mice were monitored every other day. (b) The 
tumors treated with Ad5 (left panel) or PBS (right panel) were harvested 7 
d after treatment for H&E staining (above) and anti-CD8 mAb staining 
(down). Arrows indicate the typical CD8+ cells. Original magnification 
×100. (c) Statistical analysis of CD8+ T cell number in Ad5 and PBS- 
treated tumor tissue samples. Ad-5, Ad-5 treatment group; PBS, PBS con-
trol group. *P<0.005. One of two experiments is shown. 
tumor. Immunohistochemical analysis with anti-CD8 anti-
body showed that Ad5 treatment led to intensive infiltration 
of CD8+ cells in the tumors (Figure 1(b), (c)).  
2.2  Oncolytic Ad5 therapy induced tumor-specific 
CD8+ T cell responses 
To evaluate weather the intratumoral treatment of Ad5 in-
duced specific anti-tumor CD8+ T cells responses, we first 
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analyzed IFN-γ production of lymphocytes in tumor drain-
ing lymph node (DLN) and spleen in different time points 
after Ad5 therapy by re-stimulated the lymphocytes with 
CMT93 tumor cells or an irrelevant control lung tumor cells 
CMT64. As shown in Figure 2, intratumoral Ad5 treatment 
induced strong T cell responses which produced high level 
of IFN-γ than the PBS control group. On day 3 after Ad5 
therapy, DLN cells from Ad5-treated mice produced almost 
two times higher IFN-γ than the cells from PBS control 
group. Even though the splenocytes produced low level of 
IFN-γ at this time, the splenocytes of Ad5-treated mice 
produced much higher level of IFN-γ than the cells of PBS 
control mice. On day 7 after Ad5 therapy, IFN-γ production 
of the splenocytes dramatically increased to two times 
higher level than that of DLN cells. Moreover, the spleno-
cytes of Ad5-treated mice produced more than two times 
higher IFN-γ than the cells of PBS control group. The in-
crease of IFN-γ production in lymphocytes induced by Ad5 
treatment was tumor specific, because in vitro restimulation 
of lymphocytes with control CMT64 lung tumor cells did 
not notably increase the IFN-γ production in Ad5-treated 
mice compared with PBS control mice. 
Next, we detected the tumor-specific CTL activities of 
lymphocytes induced by Ad5 treatment. The splenocytes 
isolated from the mice 7 d after treatment were re-    
stimulated with CMT93 tumor cells, and their cytotoxicity 
against CMT93 tumor and control CMT64 tumor were de-
tected by lactate dehydrogenase (LDH) release assay. As 
shown in Figure 3, the CTL activity of Ad5-treated mice 
was increased more than three times at an effector-to-target 
ratio of 40:1 compared with that of PBS-treated animals. 
The CTL activity appeared to be specific for the transplant-
ed CMT93 tumor because the syngeneic CMT64 lung can-
cer cells were not lysed.  
The above results demonstrated that intratumoral onco-
lytic adenovirus therapy could induce tumor-specific CD8+ 
T cell responses, which were required for therapeutic effi-
cacy of adenovirus.  
2.3  Ad5 therapy induced tumor-specific memory im-
mune response 
To determine whether the anti-tumor CD8+ T cell responses 
initiated by Ad5 therapy resulted in memory, the hallmark 
of adaptive immune response, we evaluated the cured mice 
for long-term protection by tumor rechallenge. The mice 
that underwent complete tumor regression following Ad5 
therapy were rechallenged with CMT93 tumor in the left  
 
 
 
Figure 2  Oncolytic Ad5 therapy induced tumor-specific IFN- production of lymphocytes. Tumors were established and treated with Ad5 or PBS as in 
Figure 1. Draining lymph nodes and spleens were harvested on days 3 or 7 after final viral treatment and stimulated with CWT93 tumors or control CWT64 
tumors for 3 d in vitro. The IFN- in the supernatants was detected by ELISA assay. CMT64 tumor cells were selected as irrelevant tumor control. *P<0.05; 
**P<0.01; ***P<0.005; ns, no significant difference. Similar results were obtained in three independent experiments. 
 
Figure 3  Increased activity of antitumor CTLs in tumor-bearing mice treated with Ad5. Tumors were established and treated with Ad5 or PBS as in Figure 
1. Splenocytes were isolated 7 d after Ad5 or PBS treatment and re-stimulated with MMC (100 µg/mL) treated CMT93 tumor cells in vitro for 4 d. Cytotoxi-
city against CMT93 or CMT64 target tumor cells were examined in LDH release assay with different effector-to-target ratios (E:T). Results are representa-
tive of two independent experiments.  
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flank (contrary side to the first inoculation) and with control 
CMT64 tumor in the right flank after primary CMT93 tu-
mor had not been detected for more than 3 months. Impres-
sively, all mice rejected the rechallenged CMT93 tumors, 
but the control CMT64 tumors grew progressively. Both 
tumors grew progressively in naive mice (Figure 4). This 
result strongly supports that Ad5 therapy-induced tumor 
regression generated long-term tumor-specific immune 
memory capable of protecting the host from rechallenge, 
and presumably against relapse.  
2.4  Anti-4-1BB mAb treatment enhance anti-tumor 
efficacy of Ad5 therapy 
Although Ad5 therapy induces specific CD8+ T cell re-
sponses against tumor, sustained immunity could be transi-
ent or diminished with the growth of tumor, or inhibited by 
immunosuppressive tumor environment. We reasoned that 
amplification and maintenance of tumor-specific CD8+ T 
cell responses initiated by Ad5 therapy could enhance the 
therapeutic effects of oncolytic adenovirus. Agonistic mAb 
to mouse 4-1BB/CD137 has been shown to be a potent 
promoter of specific CD8+ CTL in established tumor mod-
els [12,13]. To evaluate the combination therapy of Ad5 and 
anti-4-1BB mAb, mice bearing larger established CMT93 
tumor were treated with intratumoral injection of Ad5 and 
intraperitoneal injection anti-4-1BB mAb. Neither Ad5 
therapy, nor anti-4-1BB mAb treatment alone was sufficient 
to control tumor growth. The tumor growth in the Ad5- 
treated group was only delayed by about two weeks com-
pared with that in PBS control group. In contrast, the com-
bination treatment resulted in rejection of all transplanted 
tumors (Figure 5). Thus, promotion of T cell responses 
against tumor could enhance the therapeutic effects of on-
colytic adenovirus.  
3  Discussion  
The lack of an immunocompetent tumor efficacy model has 
been a critical limitation for the field of oncolytic adenovi-
rus therapy because the use of immunodeficient mice bear-
ing human xenograft tumors fails to fully assess the safety 
of replicating vectors as well as the effect of the immune 
system on the vector or the tumor [7,8,11]. Despite adeno-
virus was thought unable to complete replicate in murine 
tumors, we previously identified four mouse tumor cell 
lines with variable permissivity for adenoviral gene expres-
sion, cytopathic effects and/or replication. Ad5 therapy lead 
to the tumor regression with acute intratumoral inflamma-
tory responses and CD8+ T cell infiltrations in immuno-
competent mice, which is much less in athymic mice [9,10]. 
Here, we subcutaneously inoculated one of the permissive 
tumor cell lines, CMT 93, a murine colorectal carcinoma, 
into immunocompetent syngeneic C57B/6 mice to evaluate 
the roles of immune components in the tumor therapy of 
adenovirus. Intratumoral injection of Ad5 induced strong 
tumor-specific CD8+ T cell responses, which were required 
for antitumor efficacy of adenovirus. Deletion of CD4+ and 
NK cells did not affect adenoviral therapy. Anti-4-1BB 
mAb, a potent enhancer of specific CD8+ CTL, has a syner-
gistic anti-tumor effect with Ad5 therapy.  
Adenoviruses have numerous interactions with immune 
response effectors. In a fully immunocompetent host, local 
intratumoral virotherapy not only primes antivirus immune 
response to control viral spread both within and outside of 
the tumor, but also induces anti-tumor immune response to 
clear tumor, both locally and distant sites of tumor growth. 
In this study, we just focused on the specific immune re-
sponse against tumor and showed that deletion of CD8+ T 
cells almost abrogated the therapeutic effects of Ad5. Alt-
hough Ad5 gene expression, and cytopathic effects in 
CMT93 tumor are comparable to that in human cells in vitro, 
the oncolytic effects of Ad5 and production of new virons in 
mouse CMT93 tumor model might be inferior to that in 
human tumor therapy based on the data from adenovirus in 
normal mouse tissues. The direct oncolytic efficacy of Ad5 
might be underestimated in this mouse tumor model. How-
ever, our results at least demonstrated that treatment of on-
colytic adenovirus could induce tumor-specific T cell   
 
 
Figure 4  Mice cured of tumors by Ad5 therapy acquired long-lasting, specific immune memory. The Ad5-treated, tumor-free mice were kept for above 3 
months and rechallenged with 2×106 CMT93 tumor cells in the left flank (contrary side to the first inoculation) and 2×105 CMT64 tumor cells in the right 
flank (n=5). Five naive age-matched mice were also challenged as controls. Tumor sizes were monitored every 3 d by a digital caliper. Similar results were 
obtained in two independent experiments. 
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Figure 5  The combination of Ad5 and anti-4-1BB mAb immunotherapy 
eradicates established large tumors. CMT93 tumor-bearing mice (n=5) 
were intratumorally injected with 1×109 pfu/injection of Ad5 or PBS on 
days 12, 15 and 18 after tumor inoculation, and intraperitoneally with 
anti-4-1BB mAb or control Ig on days 14, 19 and 24. Tumor sizes were 
monitored every other day using a digital caliper. Results are representative 
of three independent experiments. 
responses, which contribute to the therapeutic effects of 
oncolytic adenovirus. 
In a fully immunocompetent host, viral oncolysis pro-
mote direct tumor destruction and tumor antigen release. 
Meantime, inflammatory milieu produced by viral replica-
tion provide ‘dangerous signal’ for host immune response, 
with the release of immunogenic intracellular contents and 
cytokine at the site of cell death. These factors favor to re-
cruit and activate APC (antigen presenting cell) and pro-
mote presentation of tumor antigens. These series of events 
provide an opportunity to activate T cells. However, tumor 
microenvironment was stressed in patients’ body and an-
ti-tumor immune responses could be tightly suppressed by 
tumor immunosuppressive environment. Furthermore, large 
tumors are often refractory to single oncolytic virus admin-
istration. The potential synergistic therapy with chemother-
apy has been described in head and neck cancer patients 
[14]. The curative effect could also be improved by adding 
immunostimulatory genes in viral vectors to enhance clear-
ance of infected tumors [15,16]. Given that the efficacy of 
adenovirus therapy is dependent on CD8+ T cells, we inves-
tigated combination therapeutic strategy of Ad5 and anti-4- 
1BB mAb, a potent stimulator of specific CD8+ T cell re-
sponses. In order to enhance immune-based anti-tumor re-
sponse while not clear virus too early to reduce oncolytic 
efficacy, we intratumorally injected Ad5 in first step which 
harnessed the property of virus replication within tumor and 
promoted tumor antigen release and presentation, then in-
traperitoneally administrated anti-4-1BB mAb, boosting the 
anti-tumor T cell response initiated by viral therapy. The 
delayed injection of anti-4-1BB mAb could avoid acceler-
ating immune-mediated clearance of the virus to more ef-
fectively enhance the therapeutic effects of oncolytic virus.  
In summary, in an immunocompetent murine tumor 
model which was permissive for infection and replication of 
adenovirus, we demonstrated that oncolytic adenoviral 
therapy could induce potent tumor-specific CD8+ T cell re-
sponses, which were critical for the therapeutic effects of 
the virus. The strategies for boosting T cell responses could 
improve the tumor therapy of oncolytic virus. This study 
proposes a model and a new and more effective therapeutic 
regime for cancer treatment by combination therapies of on-
colytic adenoviruse and targeted antibody immunotherapy. 
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